Effects of Vaccination Day Routine Activities on Influenza Vaccine Efficacy and Vaccination-Induced Adverse Reaction Incidence: A Cohort Study
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Participants
2.3. Setting
2.4. Details of the Questionnaire
2.5. Incidence of Influenza
2.6. Definition of Underlying Conditions
2.7. Data Analysis of Participants’ Background Characteristics
2.8. Main Factors
- Personal hygiene: control (no washing, wipe only, or shower only) vs. bath.
- Smoking: control (nonsmoker) vs. previous smoker, smoker but did not smoke on the vaccination day, or smoker and smoked on the vaccination day.
- Alcohol consumption: control (did not consume alcohol on the vaccination day) vs. consumed alcohol on the vaccination day.
- Caffeine intake: control (no caffeine) vs. consumed caffeine.
- Exercise: control (did not exercise on the vaccination day) vs. exercised on the vaccination day.
2.9. Main Outcome Markers
- Contracted influenza during the season: no/yes.
- Adverse reaction after vaccination
- Some types of adverse reaction: none, local, or systemic adverse reaction.
- Local adverse reaction: none and some types of local adverse reaction.
- Systemic adverse reaction: none and some types of systemic adverse reaction.
2.10. Statistical Analysis
- Model 1
- Rough analysis.
- Model 2
- Adjustment for sex, age, and underlying conditions.
- Model 3
- Model 2 + adjustment for routine activities (personal hygiene, smoking, alcohol consumption, caffeine intake, and exercise).
3. Results
4. Discussion
Limitations
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- National Institute of Infectious Diseases. Infectious Agents Surveillance Report (IASR). Influenza 2019/20 season. IASR 2020, 41, 191–193. Available online: https://www.niid.go.jp/niid/ja/flu-m/flu-iasrtpc/9961-489t.html (accessed on 31 January 2021). (In Japanese).
- Woolpert, T.; Phillips, C.J.; Sevick, C.; Crum-Cianflone, N.F.; Blair, P.J.; Faix, D. Health-related behaviors and effectiveness of trivalent inactivated versus live attenuated influenza vaccine in preventing influenza-like illness among young adults. PLoS ONE 2014, 9, e102154. [Google Scholar] [CrossRef] [PubMed]
- Wong, C.-M.; Lai, H.-K.; Ou, C.-Q.; Ho, D.S.Y.; Chan, K.-P.; Thach, T.-Q.; Yang, L.; Chau, Y.-K.; Lam, T.-H.; Hedley, A.J.; et al. Is exercise protective against influenza-associated mortality? PLoS ONE 2008, 3, e2108. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lawrence, H.; Hunter, A.; Murray, R.; Lim, W.S.; McKeever, T. Cigarette smoking and the occurrence of influenza—Systematic review. J. Infect. 2019, 79, 401–406. [Google Scholar] [CrossRef] [PubMed]
- Meyerholz, D.K.; Edsen-Moore, M.; McGill, J.; Coleman, R.A.; Cook, R.T.; Legge, K.L. Chronic alcohol consumption increases the severity of murine influenza virus infections. J. Immunol. 2008, 181, 641–648. [Google Scholar] [CrossRef] [PubMed]
- Hwang, S.M.; Choe, K.W.; Cho, S.H.; Yoon, S.J.; Park, D.E.; Kang, J.S.; Kim, M.J.; Chun, B.C.; Lee, S.M. The adverse events of influenza A (H1N1) vaccination and its risk factors in healthcare personnel in 18 military healthcare units in Korea. Jpn. J. Infect. Dis. 2011, 64, 183–189. [Google Scholar] [PubMed]
- The Review Committee for Vaccination Guidelines. Vaccination Guidelines 1994 Version; Public Foundation of the Vaccination Research Center: Tokyo, Japan, 1994. (In Japanese)
- Watanabe, K.; Matsumoto, S.; Toyoshima, E.; Ishigami, K.; Ohsaki, Y. Adverse drug reaction following quadraivalent influenza vaccination coverage of health care workers. Jpn. J. Environ. Infect. 2016, 31, 397–401. [Google Scholar] [CrossRef] [Green Version]
- Shinkai, S.; Kohno, H.; Kimura, K.; Komura, T.; Asai, H.; Inai, R.; Oka, K.; Kurokawa, Y.; Shephard, R. Physical activity and immune senescence in men. Med. Sci. Sports Exerc. 1995, 27, 1516–1526. [Google Scholar] [CrossRef] [PubMed]
- Kohut, M.L.; Cooper, M.M.; Nickolaus, M.S.; Russell, D.R.; Cunnick, J.E. Exercise and psychosocial factors modulate immunity to influenza vaccine in elderly individuals. J. Gerontol. A Biol. Sci. Med. Sci. 2002, 57, M557–M562. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pedersen, B.K.; Hoffman-Goetz, L. Exercise and the immune system: Regulation, integration, and adaptation. Physiol. Rev. 2000, 80, 1055–1081. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Noah, T.L.; Zhou, H.; Jaspers, I. Alteration of the nasal responses to influenza virus by tobacco smoke. Curr. Opin. Allergy Clin. Immunol. 2012, 12, 24–31. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Noah, T.L.; Zhou, H.; Monaco, J.; Horvath, K.; Herbst, M.; Jaspers, I. Tobacco smoke exposure and altered nasal responses to live attenuated influenza virus. Environ. Health Perspect 2011, 119, 78–83. [Google Scholar] [CrossRef] [PubMed]
- Christian, L.M.; Porter, K.; Karlsson, E.; Schultz-Cherry, S. Proinflammatory cytokine responses correspond with subjective side effects after influenza virus vaccination. Vaccine 2015, 33, 3360–3366. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zimmer, P.; Baumann, F.T.; Bloch, W.; Zopf, E.M.; Schulz, S.; Latsch, J.; Schollmayer, F.; Shimabukuro-Vornhagen, A.; von Bergwelt-Baildon, M.; Schenk, A. Impact of a half marathon on cellular immune system, pro-inflammatory cytokine levels, and recovery behavior of breast cancer patients in the aftercare compared to healthy controls. Eur. J. Haematol. 2016, 96, 152–159. [Google Scholar] [CrossRef] [PubMed]
- Cadorna-Carlos, J.B.; Nolan, T.; Borja-Tabora, C.F.; Santos, J.; Montalban, M.C.; de Looze, F.J.; Eizenberg, P.; Hall, S.; Dupuy, M.; Hutagalung, Y.; et al. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial. Vaccine 2015, 33, 2485–2492. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kenzaka, T.; Kumabe, A.; Kosami, K.; Matsuoka, Y.; Minami, K.; Ninomiya, D.; Noda, A.; Okayama, M. Physicians’ opinions regarding the criteria for resuming oral intake after aspiration pneumonia: A questionnaire survey and cluster analysis of hospitals across Japan. Geriatr. Gerontol. Int. 2017, 17, 810–818. [Google Scholar] [CrossRef] [Green Version]
- Japan Tobacco Inc. National Tobacco Smoker Rate Survey 2018. Available online: http://www.health-net.or.jp/tobacco/product/pd090000.html (accessed on 31 January 2021). (In Japanese).
- Ministry of Health, Labour and Welfare, Japan. Status of Drinking Habits. Available online: https://www.mhlw.go.jp/topics/bukyoku/kenkou/alcohol/siryo/insyu03.html (accessed on 31 January 2021). (In Japanese)
- Ministry of Health, Labour and Welfare, Japan. Status of Exercise Habits. Available online: https://www.mhlw.go.jp/content/10904750/000351576.pdf#search=%27%E9%81%8B%E5%8B%95%E7%BF%92%E6%85%A3+%E5%8E%9A%E7%94%9F%E5%8A%B4%E5%83%8D%E7%9C%81%27 (accessed on 31 January 2021). (In Japanese)
Background Characteristics | Overall | Tamba | Toyooka | Shiso | ||||
---|---|---|---|---|---|---|---|---|
n = 2731 | n = 1126 | n = 1127 | n = 478 | |||||
n | % | n | % | n | % | n | % | |
Sex | ||||||||
Female | 2069 | 76.18 | 826 | 73.49 | 887 | 79.55 | 356 | 74.63 |
Male | 647 | 23.82 | 298 | 26.51 | 228 | 20.45 | 121 | 25.37 |
Unknown | 15 | 2 | 12 | 1 | ||||
Age (years: mean, SD) | 42.70 | 12.71 | 44.13 | 13.65 | 41.28 | 12.15 | 42.71 | 11.25 |
Unknown | 50 | 18 | 22 | 10 | ||||
Pregnant (female only) | ||||||||
No | 1940 | 98.08 | 777 | 98.11 | 828 | 98.1 | 335 | 97.95 |
Yes | 38 | 1.92 | 15 | 1.89 | 16 | 1.9 | 7 | 2.05 |
Unknown | 91 | 34 | 43 | 14 | ||||
Cancer/malignant tumor | ||||||||
No | 2550 | 99.22 | 1031 | 99.42 | 1065 | 99.35 | 454 | 98.48 |
Yes | 20 | 0.78 | 6 | 0.58 | 7 | 0.65 | 7 | 1.52 |
Unknown | 161 | 89 | 55 | 17 | ||||
Immunological disease/diseases caused by steroid use | ||||||||
No | 2558 | 99.46 | 1033 | 99.61 | 1068 | 99.44 | 457 | 99.13 |
Yes | 14 | 0.54 | 4 | 0.39 | 6 | 0.56 | 4 | 0.87 |
Unknown | 159 | 89 | 53 | 17 | ||||
Renal disease | ||||||||
No | 2559 | 99.53 | 1033 | 99.61 | 1068 | 99.53 | 1068 | 99.53 |
Yes | 12 | 0.47 | 4 | 0.39 | 5 | 0.47 | 5 | 0.47 |
Unknown | 160 | 89 | 54 | −595 | ||||
Diabetes | ||||||||
No | 2558 | 99.49 | 1030 | 99.32 | 1069 | 99.72 | 459 | 99.35 |
Yes | 13 | 0.51 | 7 | 0.68 | 3 | 0.28 | 3 | 0.65 |
Unknown | 160 | 89 | 55 | 16 | ||||
Hepatic disease | ||||||||
No | 2562 | 99.69 | 1032 | 99.52 | 1070 | 99.81 | 460 | 99.78 |
Yes | 8 | 0.31 | 5 | 0.48 | 2 | 0.19 | 1 | 0.22 |
Unknown | 161 | 89 | 55 | 17 | ||||
Pulmonary disease | ||||||||
No | 2542 | 98.8 | 1026 | 98.65 | 1060 | 98.88 | 456 | 98.92 |
Yes | 31 | 1.2 | 14 | 1.35 | 12 | 1.12 | 5 | 1.08 |
Unknown | 158 | 86 | 55 | 17 | ||||
Body temperature at the time of vaccination (°C: mean, SD) | 36.39 | 0.36 | 36.40 | 0.34 | 36.39 | 0.37 | 36.34 | 0.36 |
Unknown | 151 | 66 | 60 | 25 | ||||
Physical condition at the time of vaccination | ||||||||
Good | 2605 | 98.15 | 1064 | 98.61 | 1077 | 97.64 | 464 | 98.31 |
Poor | 49 | 1.85 | 15 | 1.39 | 26 | 2.36 | 8 | 1.69 |
Unknown | 77 | 47 | 24 | 6 | ||||
History of influenza vaccination | ||||||||
No | 127 | 4.68 | 62 | 5.55 | 40 | 3.57 | 25 | 5.26 |
Yes | 2584 | 95.32 | 1055 | 94.45 | 1079 | 96.43 | 450 | 94.74 |
Unknown | 20 | 9 | 8 | 3 | ||||
Food/drug allergies | ||||||||
No | 2380 | 88.12 | 994 | 89.87 | 968 | 86.43 | 418 | 88 |
Yes | 321 | 11.88 | 112 | 10.13 | 152 | 13.57 | 57 | 12 |
Unknown | 30 | 20 | 7 | 3 | ||||
Personal hygiene status after vaccination on vaccination day | ||||||||
Bath | 1882 | 70.57 | 739 | 66.76 | 760 | 69.79 | 383 | 81.32 |
Shower only | 699 | 26.21 | 317 | 28.64 | 308 | 28.28 | 74 | 15.71 |
Wiping | 30 | 1.12 | 20 | 1.81 | 4 | 0.37 | 6 | 1.27 |
No washing | 56 | 2.1 | 31 | 2.8 | 17 | 1.56 | 8 | 1.7 |
Unknown | 64 | 19 | 38 | 7 | ||||
Alcohol consumption after vaccination on vaccination day | ||||||||
No | 2245 | 83.03 | 935 | 83.56 | 939 | 84.52 | 371 | 78.27 |
Yes | 459 | 16.97 | 184 | 16.44 | 172 | 15.48 | 103 | 21.73 |
Unknown | 27 | 7 | 16 | 4 | ||||
Caffeine intake after vaccination on vaccination day | ||||||||
No | 1312 | 49.83 | 606 | 55.29 | 508 | 47.43 | 198 | 42.49 |
Yes | 1321 | 50.17 | 490 | 44.71 | 563 | 52.57 | 268 | 57.51 |
Unknown | 98 | 30 | 56 | 12 | ||||
Smoking after vaccination on vaccination day | ||||||||
Nonsmoker | 2231 | 82.23 | 924 | 82.43 | 938 | 84.13 | 369 | 77.36 |
Previous smoker | 299 | 11.02 | 134 | 11.95 | 96 | 8.61 | 69 | 14.47 |
Smoker, no smoking on the day of vaccination | 11 | 0.41 | 9 | 0.8 | 2 | 0.18 | 0 | 0 |
Smoker, smoked on vaccination day | 172 | 6.34 | 54 | 4.82 | 79 | 7.09 | 39 | 8.18 |
Unknown | 18 | 5 | 12 | 1 | ||||
Exercise after vaccination on vaccination day | ||||||||
No | 2574 | 95.05 | 1077 | 96.07 | 1060 | 95.5 | 437 | 91.61 |
Yes | 134 | 4.95 | 44 | 3.93 | 50 | 4.5 | 40 | 8.39 |
Unknown | 23 | 5 | 17 | 1 | ||||
Contracted influenza in 2018–2020 or had an adverse reaction | ||||||||
Contracted influenza | ||||||||
No | 2585 | 94.65 | 1086 | 96.45 | 1061 | 94.14 | 438 | 91.63 |
Yes | 146 | 5.35 | 40 | 3.55 | 66 | 5.86 | 40 | 8.37 |
Unknown | 0 | 0 | 0 | 0 | ||||
Type of influenza contracted | ||||||||
A | 114 | 78.08 | 36 | 90 | 53 | 80.3 | 25 | 62.5 |
B | 15 | 10.27 | 2 | 5 | 13 | 19.7 | 0 | 0 |
A + B | 1 | 0.68 | 1 | 2.5 | 0 | 0 | 0 | 0 |
Unknown | 16 | 10.96 | 1 | 2.5 | 0 | 0 | 15 | 37.5 |
Redness at the injection site | ||||||||
No | 1001 | 36.95 | 554 | 49.38 | 281 | 25.2 | 166 | 35.17 |
Yes | 1708 | 63.05 | 568 | 50.62 | 834 | 74.8 | 306 | 64.83 |
Unknown | 22 | 4 | 12 | 6 | ||||
Swelling at the injection site | ||||||||
No | 1020 | 37.71 | 529 | 47.11 | 320 | 28.83 | 171 | 36.23 |
Yes | 1685 | 62.29 | 594 | 52.89 | 790 | 71.17 | 301 | 63.77 |
Unknown | 26 | 3 | 17 | 6 | ||||
Induration at the injection site | ||||||||
No | 1882 | 70.07 | 808 | 72.6 | 752 | 68.24 | 322 | 68.37 |
Yes | 804 | 29.93 | 305 | 27.4 | 350 | 31.76 | 149 | 31.63 |
Unknown | 45 | 13 | 25 | 7 | ||||
Pain at the injection site | ||||||||
No | 1413 | 52.31 | 647 | 57.66 | 518 | 46.92 | 248 | 52.21 |
Yes | 1288 | 47.69 | 475 | 42.34 | 586 | 53.08 | 227 | 47.79 |
Unknown | 30 | 4 | 23 | 3 | ||||
Heat sensation at the injection site | ||||||||
No | 1329 | 48.97 | 658 | 58.75 | 442 | 39.5 | 229 | 48.21 |
Yes | 1385 | 51.03 | 462 | 41.25 | 677 | 60.5 | 246 | 51.79 |
Unknown | 17 | 6 | 8 | 3 | ||||
Itching at the injection site | ||||||||
No | 1447 | 53.45 | 734 | 65.65 | 474 | 42.4 | 239 | 50.74 |
Yes | 1260 | 46.55 | 384 | 34.35 | 644 | 57.6 | 232 | 49.26 |
Unknown | 24 | 8 | 9 | 7 | ||||
Heaviness/lassitude at the injection site | ||||||||
No | 2145 | 79.77 | 910 | 81.69 | 860 | 77.62 | 375 | 80.3 |
Yes | 544 | 20.23 | 204 | 18.31 | 248 | 22.38 | 92 | 19.7 |
Unknown | 42 | 12 | 19 | 11 | ||||
Other localized symptoms | ||||||||
No | 2470 | 98.33 | 1039 | 98.58 | 983 | 98.3 | 448 | 97.82 |
Yes | 42 | 1.67 | 15 | 1.42 | 17 | 1.7 | 10 | 2.18 |
Unknown | 219 | 72 | 127 | 20 | ||||
Some types of localized symptoms | ||||||||
No | 491 | 18.33 | 280 | 25.34 | 124 | 11.25 | 87 | 18.43 |
Yes | 2188 | 81.67 | 825 | 74.66 | 978 | 88.75 | 385 | 81.57 |
Unknown | 52 | 21 | 25 | 6 | ||||
Fever | ||||||||
No | 2672 | 98.34 | 1104 | 98.13 | 1098 | 98.04 | 470 | 99.58 |
Yes | 45 | 1.66 | 21 | 1.87 | 22 | 1.96 | 2 | 0.42 |
Unknown | 14 | 1 | 7 | 6 | ||||
Chills | ||||||||
No | 2673 | 98.34 | 1105 | 98.22 | 1102 | 98.39 | 466 | 98.52 |
Yes | 45 | 1.66 | 20 | 1.78 | 18 | 1.61 | 7 | 1.48 |
Unknown | 13 | 1 | 7 | 5 | ||||
Headache | ||||||||
No | 2588 | 95.11 | 1076 | 95.64 | 1059 | 94.39 | 453 | 95.57 |
Yes | 133 | 4.89 | 49 | 4.36 | 63 | 5.61 | 21 | 4.43 |
Unknown | 10 | 1 | 5 | 4 | ||||
Fatigue | ||||||||
No | 2486 | 91.33 | 1036 | 92.09 | 1022 | 91.09 | 428 | 90.11 |
Yes | 236 | 8.67 | 89 | 7.91 | 100 | 8.91 | 47 | 9.89 |
Unknown | 9 | 1 | 5 | 3 | ||||
Nasal discharge | ||||||||
No | 2618 | 96.21 | 1093 | 97.07 | 1073 | 95.72 | 452 | 95.36 |
Yes | 103 | 3.79 | 33 | 2.93 | 48 | 4.28 | 22 | 4.64 |
Unknown | 10 | 0 | 6 | 4 | ||||
Cough | ||||||||
No | 2658 | 97.61 | 1101 | 97.78 | 1090 | 97.06 | 467 | 98.52 |
Yes | 65 | 2.39 | 25 | 2.22 | 33 | 2.94 | 7 | 1.48 |
Unknown | 8 | 0 | 4 | 4 | ||||
Nausea | ||||||||
No | 2698 | 99.19 | 1114 | 99.02 | 1116 | 99.55 | 468 | 98.73 |
Yes | 22 | 0.81 | 11 | 0.98 | 5 | 0.45 | 6 | 1.27 |
Unknown | 11 | 1 | 6 | 4 | ||||
Diarrhea | ||||||||
No | 2682 | 98.64 | 1105 | 98.22 | 1107 | 98.75 | 470 | 99.37 |
Yes | 37 | 1.36 | 20 | 1.78 | 14 | 1.25 | 3 | 0.63 |
Unknown | 12 | 1 | 6 | 5 | ||||
Difficulty moving the upper limbs | ||||||||
No | 2523 | 92.86 | 1047 | 93.15 | 1032 | 92.06 | 444 | 94.07 |
Yes | 194 | 7.14 | 77 | 6.85 | 89 | 7.94 | 28 | 5.93 |
Unknown | 14 | 2 | 6 | 6 | ||||
Numbness | ||||||||
No | 2677 | 98.42 | 1107 | 98.49 | 1103 | 98.31 | 467 | 98.52 |
Yes | 43 | 1.58 | 17 | 1.51 | 19 | 1.69 | 7 | 1.48 |
Unknown | 11 | 2 | 5 | 4 | ||||
Other systemic symptoms | ||||||||
No | 2593 | 98.41 | 1071 | 97.81 | 1054 | 98.6 | 468 | 99.36 |
Yes | 42 | 1.59 | 24 | 2.19 | 15 | 1.4 | 3 | 0.64 |
Unknown | 96 | 31 | 58 | 7 | ||||
Some types of systemic symptoms | ||||||||
No | 2129 | 80.01 | 887 | 80.49 | 868 | 79.63 | 374 | 79.74 |
Yes | 532 | 19.99 | 215 | 19.51 | 222 | 20.37 | 95 | 20.26 |
Unknown | 70 | 24 | 37 | 9 | ||||
Some types of systemic or localized symptoms | ||||||||
No | 465 | 17.34 | 263 | 23.76 | 118 | 10.71 | 84 | 17.8 |
Yes | 2216 | 82.66 | 844 | 76.24 | 984 | 89.29 | 388 | 82.2 |
Unknown | 50 | 19 | 25 | 6 |
Lifestyle Factors | Contracted Influenza | ||
---|---|---|---|
RR (95% CI) | |||
Model 1 | Model 2 | Model 3 | |
Personal hygiene | |||
Bathing | 1.09 (0.76–1.56) | 1.25 (0.85–1.83) | 1.20 (0.80–1.79) |
Smoking | |||
Previous smoker | 1.22 (0.76–1.96) | 1.33 (0.81–2.21) | 1.35 (0.79–2.30) |
Smoker, did not smoke on the vaccination day | Not estimated | Not estimated | Not estimated |
Smoker, smoked on the vaccination day | 1.12 (0.60–2.09) | 1.13 (0.58–2.21) | 1.17 (0.58–2.36) |
Alcohol consumption | |||
Yes | 1.03 (0.68–1.56) | 1.12 (0.72–1.72) | 1.15 (0.73–1.80) |
Caffeine intake | |||
Yes | 0.81 (0.58–1.12) | 0.89 (0.63–1.25) | 0.88 (0.62–1.25) |
Exercise | |||
Yes | 0.83 (0.37–1.84) | 0.71 (0.30–1.71) | 0.78 (0.33–1.86) |
Lifestyle Factors | Some Types of Adverse Reactions Observed | ||
---|---|---|---|
RR (95% CI) | |||
Model 1 | Model 2 | Model 3 | |
Personal hygiene | |||
Bathing | 1.00 (0.96–1.04) | 0.99 (0.96–1.03) | 1.00 (0.96–1.04) |
Smoking | |||
Previous smoker | 0.91 (0.85–0.97) | 1.00 (0.94–1.07) | 1.00 (0.93–1.07) |
Smoker, did not smoke on vaccination day | 0.76 (0.48–1.18) | 0.82 (0.52–1.29) | 0.77 (0.45–1.34) |
Smoker, smoked on vaccination day | 0.90 (0.82–0.98) | 1.01 (0.92–1.10) | 1.00 (0.91–1.10) |
Alcohol consumption | |||
Yes | 0.93 (0.89–0.98) | 1.01 (0.96–1.06) | 1.00 (0.95–1.06) |
Caffeine intake | |||
Yes | 1.01 (0.97–1.04) | 1.02 (0.99–1.06) | 1.02 (0.98–1.06) |
Exercise | |||
Yes | 0.96 (0.88–1.05) | 1.05 (0.97–1.14) | 1.06 (0.98–1.15) |
Lifestyle Factors | Incidence of Local Adverse Reactions | ||
---|---|---|---|
RR (95% CI) | |||
Model 1 | Model 2 | Model 3 | |
Personal hygiene | |||
Bathing | 1.00 (0.96–1.04) | 0.99 (0.96–1.04) | 1.00 (0.96–1.04) |
Smoking | |||
Previous smoker | 0.91 (0.85–0.97) | 1.01 (0.95–1.09) | 1.01 (0.94–1.08) |
Smoker, did not smoke on the vaccination day | 0.76 (0.49–1.19) | 0.84 (0.54–1.31) | 0.79 (0.46–1.37) |
Smoker, smoked on the vaccination day | 0.88 (0.81–0.97) | 1.00 (0.91–1.10) | 0.99 (0.90–1.09) |
Alcohol consumption | |||
Yes | 0.92 (0.87–0.98) | 1.00 (0.95–1.06) | 1.00 (0.95–1.06) |
Caffeine intake | |||
Yes | 1.02 (0.98–1.05) | 1.03 (1.00–1.07) | 1.03 (0.99–1.07) |
Exercise | |||
Yes | 0.95 (0.86–1.04) | 1.04 (0.95–1.13) | 1.06 (0.97–1.15) |
Lifestyle Factors | Incidence of Systemic Adverse Reactions | ||
---|---|---|---|
RR (95% CI) | |||
Model 1 | Model 2 | Model 3 | |
Personal hygiene | |||
Bathing | 1.01 (0.85–1.19) | 1.03 (0.86–1.24) | 1.04 (0.87–1.26) |
Smoking | |||
Previous smoker | 0.89 (0.68–1.15) | 0.99 (0.75–1.31) | 0.98 (0.73–1.31) |
Smoker, did not smoke on the vaccination day | 0.44 (0.07–2.87) | 0.72 (0.11–4.75) | Not estimated |
Smoker, smoked on the vaccination day | 0.83 (0.59–1.17) | 1.00 (0.69–1.44) | 0.88 (0.58–1.33) |
Alcohol consumption | |||
Yes | 0.97 (0.79–1.19) | 1.07 (0.86–1.34) | 1.07 (0.85–1.34) |
Caffeine intake | |||
Yes | 0.99 (0.85–1.15) | 1.00 (0.85–1.18) | 0.99 (0.84–1.17) |
Exercise | |||
Yes | 1.20 (0.88–1.65) | 1.35 (0.99–1.85) | 1.44 (1.06–1.97) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kenzaka, T.; Yahata, S.; Goda, K.; Kumabe, A.; Kamada, M.; Okayama, M. Effects of Vaccination Day Routine Activities on Influenza Vaccine Efficacy and Vaccination-Induced Adverse Reaction Incidence: A Cohort Study. Vaccines 2021, 9, 753. https://doi.org/10.3390/vaccines9070753
Kenzaka T, Yahata S, Goda K, Kumabe A, Kamada M, Okayama M. Effects of Vaccination Day Routine Activities on Influenza Vaccine Efficacy and Vaccination-Induced Adverse Reaction Incidence: A Cohort Study. Vaccines. 2021; 9(7):753. https://doi.org/10.3390/vaccines9070753
Chicago/Turabian StyleKenzaka, Tsuneaki, Shinsuke Yahata, Ken Goda, Ayako Kumabe, Momoka Kamada, and Masanobu Okayama. 2021. "Effects of Vaccination Day Routine Activities on Influenza Vaccine Efficacy and Vaccination-Induced Adverse Reaction Incidence: A Cohort Study" Vaccines 9, no. 7: 753. https://doi.org/10.3390/vaccines9070753
APA StyleKenzaka, T., Yahata, S., Goda, K., Kumabe, A., Kamada, M., & Okayama, M. (2021). Effects of Vaccination Day Routine Activities on Influenza Vaccine Efficacy and Vaccination-Induced Adverse Reaction Incidence: A Cohort Study. Vaccines, 9(7), 753. https://doi.org/10.3390/vaccines9070753